Alprostadil topical - Apricus Biosciences

Drug Profile

Alprostadil topical - Apricus Biosciences

Alternative Names: Alprox-TD; Befar; Cold Chain Vitaros; Femprox; RayVa; Room Temperature Vitaros; Topical ED treatment - Apricus; Virirec; Vitaros; Vytaros; WC-3036

Latest Information Update: 30 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator NexMed
  • Developer Apricus Biosciences; Ferring Pharmaceuticals; Laboratoires Majorelle; Recordati
  • Class Erectile dysfunction therapies; Monounsaturated fatty acids; Muscle relaxants; Peripheral vasodilators; Prostaglandins; Small molecules
  • Mechanism of Action Prostaglandin E1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Erectile dysfunction; Female sexual dysfunction; Raynaud's disease

Highest Development Phases

  • Marketed Erectile dysfunction
  • Phase II Raynaud's disease
  • Suspended Female sexual dysfunction
  • No development reported Premature ejaculation; Wounds

Most Recent Events

  • 11 May 2017 Apricus Biosciences sells ex-US rights of alprostadil topical to Ferring Pharmaceuticals
  • 13 Mar 2017 Apricus Biosciences announces intention to re-submit the NDA for Alprostadil for the treatment of Erectile dysfunction in the third quarter of 2017
  • 13 Mar 2017 Apricus Biosciences plans a meeting with the FDA's office of Product Quality to confirm the necessary device engineering and compliance requirements for the Alprostadil NDA re-submission in the second quarter of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top